• Alcon acquired Neurotech Pharmaceuticals for $550 million, expanding its retina portfolio with ENCELTO.
• Additional contingent payments may be required, including upon achievement of commercial milestones.
• ENCELTO is the only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2, a progressive retinal disease.
• The therapy received FDA approval in March 2025 and is available only in the U.S.
• The transaction is expected to modestly boost net sales growth, slightly dilute core diluted EPS in 2027 and be accretive thereafter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alcon AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20261020151062) on October 20, 2026, and is solely responsible for the information contained therein.